Octane Medical Group

The Cocoon platform is Octane’s proprietary automated bioreactor system for cell therapy manufacturing. It functions as both a licensable technology — Octane partners with firms like Lonza to deploy Cocoon production systems — and an internal production backbone for Octane’s own ventures, such as Octane Biotherapeutics. This dual-use design lets the group generate partnership revenue while retaining the manufacturing capability to scale its own cell therapy products, a configuration rare among pure-play CDMOs or biotech startups.

Octane acquired them. In June 2024, the group bought B. Braun’s global orthobiologics business, which brought TETEC AG in Germany and Aesculap Biologics in the United States under Octane’s control (per the firm, June 2024). In March 2026, it signed an agreement to acquire Lonza’s Personalized Medicine business, adding a full-scale cell therapy CDMO operation (per the firm, March 2026). Rather than building from scratch, Octane used acquisitions to instantly gain commercial-scale manufacturing and distribution in orthobiologics and personalized medicine.

There is no public evidence Octane raises external funds or operates as a traditional investment vehicle. The group describes itself through its ventures — Octane Biotech, Octane CDMO, and others — each structured as a market-specific operating company. This suggests Octane functions as a corporate group that develops its own technology and acquires operating businesses, rather than pooling third-party capital to invest in outside startups.

Octane does not publicly name its executive team, board, or investment committee on its website. The firm’s “Our Vision and Team” page references only the group’s mission and venture structure without identifying individuals. For an institutional allocator or co-investor, the lack of named decision-makers would require direct inquiry before entering any partnership or co-investment.

Octane’s manufacturing footprint stretches across Canada, the United States, and Europe. The group’s headquarters and likely early-stage R&D sit in Kingston, Ontario. The 2024 acquisition of TETEC AG and Aesculap Biologics added operational sites in Germany and the United States, while the pending Lonza Personalized Medicine deal would further expand European and North American capacity. Its partnership with BioOra, signed in April 2026, targets manufacturing and distribution in New Zealand, Australia, and North America.